Continuous Aortic Flow Augmentation

A Pilot Study of Hemodynamic and Renal Responses to a Novel Percutaneous Intervention in Decompensated Heart Failure

Marvin A. Konstam, MD; Barbara Czerska, MD; Michael Böhm, MD, PhD; Ron M. Oren, MD; Jerzy Sadowski, MD, PhD; Sanjaya Khanal, MD; William T. Abraham, MD; Andrae Wasler, MD; Johannes B. Dahm, MD; Antonello Gavazzi, MD; Sinisa Gradinac, MD, PhD; Victor Legrand, MD; Paul Mohacsi, MD; Gerhard Poelzl, MD; Branislav Radovancevic, MD; Adrian B. Van Bakel, MD; Michael R. Zile, MD; Barry Cabuay, MD; Krzysztof Bartus, MD; Piet Jansen, MD

Background—Diminished aortic flow may induce adverse downstream vascular and renal signals. Investigations in a heart failure animal model have shown that continuous aortic flow augmentation (CAFA) achieves hemodynamic improvement and ventricular unloading, which suggests a novel therapeutic approach to patients with heart failure exacerbation that is inadequately responsive to medical therapy.

Methods and Results—We studied 24 patients (12 in Europe and 12 in the United States) with heart failure exacerbation that is inadequately responsive to medical therapy. CAFA (mean±SD 1.34±0.12 L/min) was achieved through percutaneous (n=19) or surgical (n=5) insertion of the Cancion system, which consists of inflow and outflow cannulas and a magnetically levitated and driven centrifugal pump. Hemodynamic improvement was observed within 1 hour. Systemic vascular resistance decreased from 1413±453 to 1136±381 dyne · s · cm−2 at 72 hours (P=0.0008). Pulmonary capillary wedge pressure decreased from 28.5±4.9 to 19.8±7.0 mm Hg (P<0.0001), and cardiac index (excluding augmented aortic flow) increased from 1.97±0.44 to 2.27±0.43 L · min−1 · m−2 (P=0.0013). Serum creatinine trended downward during treatment (overall P=0.095). There were 8 complications during treatment, 7 of which were self-limited. Hemodynamics remained improved 24 hours after CAFA discontinuation.

Conclusions—In patients with heart failure and persistent hemodynamic derangement despite intravenous inotropic and/or vasodilator treatment, CAFA improved hemodynamics, with a reduction in serum creatinine. CAFA represents a promising, novel mode of treatment for patients who are inadequately responsive to medical therapy. The clinical impact of the observed hemodynamic improvement is currently being explored in a prospective, randomized, controlled trial. (Circulation. 2005;112:3107-3114.)

Key Words: heart failure ■ hemodynamics ■ vasodilation ■ nitric oxide ■ heart-assist device

The prevalence of heart failure among Americans is nearly 5 million, with more than 500,000 newly diagnosed cases each year.1 There are approximately 1 million annual US hospitalizations with the primary diagnosis of heart failure, with an estimated 44% of discharged patients readmitted within 6 months.1,2 Although medical therapy for chronic heart failure has advanced substantially, improvements in the treatment of decompensated heart failure have lagged behind.3 Various types of mechanical circulatory support devices are approved for clinical practice, as a bridge to cardiac transplantation or as destination therapy.4,5 Although selection of the type of device is based on type of heart failure, size of the patient, and experience of the institution, the main objective is to functionally supplement or replace flow from the failing ventricles in patients with decompensated heart failure. The placement of these devices, which pump blood from the left ventricle (LV) into the aorta, requires major

Received January 11, 2005; de novo received April 12, 2005; revision received August 10, 2005; accepted August 11, 2005.

From Tufts-New England Medical Center and Tufts University (M.A.K.), Boston, Mass; Henry Ford Heart & Vascular Institute (B.C., S.K.), Detroit, Mich; University Hospital Saarland (M.B.), Homburg, Germany; University of Iowa (R.M.O., B.C.), Iowa City, Iowa; Jagiellonian University (J.S., K.B.), Krakow, Poland; The Ohio State University (W.T.A.), Columbus, Ohio; University Hospital Graz (A.W.), Graz, Austria; University Hospital (J.B.D.), Greifswald, Germany; Riuniti Hospital (A.G.), Bergamo, Italy; Dedinje Cardiovascular Institute (S.G.), Belgrade, Yugoslavia, Sart Tilman University Hospital (V.L.), Liege, Belgium; University Hospital Bern (P.M.), Bern, Switzerland; University Hospital Innsbruck (G.P.), Innsbruck, Austria; Texas Heart Institute at St. Luke’s Episcopal Hospital (B.R.), Houston, Tex; Medical University of South Carolina (A.B.V.B., M.R.Z.), Charleston, SC; and Orqis Medical (P.J.), Lake Forest, Calif.

Correspondence to Marvin A. Konstam, MD, Tufts-New England Medical Center, 750 Washington St, Boston, MA 02111. E-mail MKonstam@tufts-nemc.org

© 2005 American Heart Association, Inc.

Circulation is available at http://www.circulationaha.org

DOI: 10.1161/CIRCULATIONAHA.105.555367
surgical expertise in specialized centers. A less invasive device, which can produce sustained hemodynamic and clinical improvement, would be desirable to fill this gap in treatment.

Investigations in a chronic, microembolic, ischemic heart failure canine model have demonstrated that institution of continuous aortic flow augmentation (CAFA), using the Cancion system (Orqis Medical Corporation), results in reduction in left heart filling pressure and volumes and augmented LV ejection fraction (EF). On the basis of the hypothesis that reduced aortic flow results in adverse downstream vascular and renal signals, this novel system comprises a miniature extracorporeal pump that augments aortic flow continuously throughout the cardiac cycle. It does not require any mechanical connection to the heart. A previous report demonstrated hemodynamic and clinical improvement with this system in a single patient with severe, decompensated heart failure. The observed salutary effects have been consistent with progressive vasodilation, ventricular unloading, and augmented renal perfusion.

We now report results from the first 24 patients undergoing CAFA with the Cancion system, who constitute the combined enrollment within feasibility trials performed in the United States and in Europe. Patients enrolled manifested acute exacerbation of chronic heart failure with hemodynamic derangement, which was uncorrected with intravenous diuretic and inotropic and/or vasodilator therapy. We report results of hemodynamics and renal function with up to 5 days of treatment.

Methods
Population
Patients were enrolled under 2 investigational protocols, one in Europe and one in the United States, with similar entry and exclusion criteria. Protocols were approved, respectively, by individual center ethics committees (Europe: 9 sites) and investigational review boards (United States: 4 sites). All patients gave written, informed consent. Entry criteria included the following: age 18 to 80 years; hospitalization owing to acute exacerbation of chronic heart failure manifesting increasing dyspnea and/or fatigue and/or exercise intolerance; need for hemodynamic monitoring, based on clinical judgment; treatment with intravenous diuretics and inotropic and/or vasodilator therapy, with either clinical response judged to be inadequate or recurrence of signs and symptoms on weaning attempt; elevated pulmonary capillary wedge pressure (PCWP; Europe: ≥20 mm Hg; United States: ≥18 mm Hg); stable drug doses (Europe: ≥2 hours; United States: ≥6 hours); reduced LVEF (Europe: ≤35%; United States: ≤25%); and abnormal renal function or high diuretic requirement (serum creatinine ≥1.5 mg%, estimated creatinine clearance ≤60 mL/min,$^{a,9}$ or intravenous furosemide dose ≥120 mg over 24 hours). Exclusion criteria included systolic blood pressure ≤80 mm Hg or clinical cardiogenic shock; recent Q-wave myocardial infarction (≤30 days) or cardiac surgery (Europe: ≤7 days; United States: ≤30 days); concomitant use of other forms of mechanical support; cerebral vascular accident or transient ischemic attack within the prior year; severe renal impairment (Europe: on dialysis; United States: on dialysis or serum creatinine >3.0 mg%); history of ventricular fibrillation or sustained ventricular tachycardia, in the absence of correctable cause, unless an implantable cardiac defibrillator was present; clinically significant peripheral vascular disease; coagulopathy or inability to receive heparin; evidence of systemic infection; and other life-threatening or debilitating disease.

Description of the Device
In animal models of heart failure, we have found that superimposing additional continuous flow onto pulsatile aortic flow within the descending aorta results in ventricular unloading and improved hemodynamics. The Cancion system consists of a pump, tubing, and arterial access cannulas and is designed to recirculate blood from the iliac artery to the descending thoracic aorta via the pigtail outflow cannula, percutaneously placed via the right femoral artery. Flow is monitored by a flow sensor, positioned on the outflow tubing, and is regulated by the controller.

Figure 1. Cancion system for CAFA. The centrifugal flow pump (a), driven by a magnetic motor (b), draws blood from the percutaneously placed inflow cannula (c), positioned in the left iliac artery, and returns to the descending thoracic aorta via the pigtail outflow cannula (d), percutaneously placed via the right femoral artery. Flow is monitored by a flow sensor (e), positioned on the outflow tubing, and is regulated by the controller (f).
femoral configuration). In the remaining 19 patients, pump outflow was via a 60-cm-long, 12F cannula inserted through a percutaneously inserted right femoral arterial sheath (femoral-femoral configuration). The terminal end-hole pigtail of the cannula was positioned under fluoroscopy in the thoracic aorta just above the level of the tracheal carina. The inflow and outflow cannulas were connected via PVC tubing to a bearingless, magnetically levitated centrifugal pump (32 mL priming volume) designed to minimize hemolysis and thrombosis. The blood capacity of the entire system (including the pump and the intracorporeal portions of the cannulas) is ≈108 mL. The pump is activated by a bearingless magnetoelectric motor connected to a controller. Pump speeds of 2000 to 5400 rpm were used to achieve flow rates of 1.1 to 1.5 L/min. When the pump is activated, the flow loop results in superimposition of additional nonpulsatile flow on pulsatile cardiac output within the descending aorta between the outflow and inflow cannulas.

In vitro and in vivo safety studies have demonstrated that the Cancion system produces a minimal or an acceptable degree of hemolysis (predefined as absence of an increase in plasma free hemoglobin to >40 mg/dL on 2 consecutive measurements) when used for up to 5 days. For the duration of circulatory support, anticoagulation with continuous infusion of unfractionated heparin was used to maintain activated partial thromboplastin time between 65 and 85 seconds. The system was inserted and removed in a cardiac catheterization laboratory (femoral-femoral) or an operating room (axillary-femoral). After insertion, the patient was transferred to an intensive care unit for the duration of device treatment, for up to 5 days. After the device was removed, the patient remained in the intensive care unit for an additional 24 hours of hemodynamic monitoring.

**Measurements**

Baseline hemodynamic measurements were performed in duplicate and were averaged. In the United States, PCWP was recorded at 6-hour intervals beginning 24 hours before device implantation. Cardiac output was determined by the thermodilution technique. After device implantation, hemodynamic and laboratory data were acquired at predefined time intervals during the study and were continued after device explantation for an additional 24 hours.

**Statistical Analysis**

Results are expressed as mean±SD, unless otherwise specified. Overall significance for each parameter was tested with linear regression, testing for a trend over time. The regression considered patients as random effects; repeated-measures analysis was used because of potential within-patient correlations. Measurements at each time point were compared with baseline values with 2-tailed paired t tests; no adjustment for multiple comparisons has been performed when reporting these probability values. Two-sided probability values are reported. Statistical computations were performed with SAS version 8.2.

Approximately 8% (27/327) of the PCWP values were missing. For pointwise comparisons against baseline and for the summary statistics, missing values were imputed with the last observation carried forward (LOCF) technique; missing values at the 1-hour time point were imputed to be the mean of the baseline and 2-hour values. This LOCF method is slightly biased against detecting a trend over time. The regressions used actual observed data only, although the same significance is obtained with the LOCF data. A similar situation prevailed with the other response variables.

**Results**

Between December 2001 and March 2004, 24 patients (12 in the United States and 12 in Europe) underwent treatment with the Cancion system (3 females, 21 males). Baseline characteristics are listed in Table 1. The average age was 54 years, with a range from 26 to 75 years. Eight patients had ischemic cardiomyopathy, 14 had idiopathic dilated cardiomyopathy, 1 had valvular heart disease, and 1 had graft arteriosclerosis 39 months after cardiac transplantation.

The Cancion system was implanted for a duration of 2 to 119 hours, with an average of 77±33 hours. Pump flows ranged between 1.07 and 1.56 L/min, with an average of 1.34±0.12 L/min. One patient (with graft arteriosclerosis) was in cardiogenic shock with hyperkalemia at the time of implantation and died 2 hours after the implantation, with continued cardiogenic shock and progressive hyperkalemia. Efficacy analysis was performed in the remaining 23 patients. Medication doses remained stable throughout the treatment period. The most commonly prescribed intravenous inotropic/vasodilator agents were dobutamine (n=17) and milrinone (n=14). Among patients completing 3 days of treatment, mean doses of dobutamine and milrinone were 6.3±3.8 and 5.6±2.7 μg·kg⁻¹·min⁻¹ and 0.48±0.21 and 0.44±0.25 μg·kg⁻¹·min⁻¹ at baseline and day 3, respectively. Daily furosemide doses averaged 134±183 and 135±128 mg at baseline and day 3, respectively.

At baseline, PCWP averaged 28.4±4.9 mm Hg, cardiac index (CI) averaged 1.94±0.42 L·min⁻¹·m⁻², and mean arterial pressure averaged 76.9±9.3 mm Hg. Table 2 lists mean hemodynamic values at baseline and throughout the first 24 hours after device implantation. Table 3 lists hemodynamic values at baseline and at 8-hour intervals up to 72 hours after device implantation, and then 12 and 24 hours after device removal, for the 20 patients who received treatment for at least 48 hours. CAFA treatment resulted in a reduction in PCWP, pulmonary artery pressure, and systemic vascular resistance (SVR) and an increase in CI. As shown in Figure 2, for US patients (in whom measurements were obtained for 24 hours before device implantation), initiation of CAFA treatment resulted in an abrupt and progressive reduction in PCWP relative to a stable baseline over the preceding 24 hours. Data for all 23 patients are shown in Figure 3. Improvements in all parameters were sustained and progressive over 72 hours of treatment. At 12 and 24 hours after removal of the device, all hemodynamic benefits were still present. Mean arterial pressure decreased from baseline during the first several hours of treatment and remained stable during the remainder of device treatment and after removal. Figure 4 plots PCWP versus CI at baseline, after 24 and 72 hours of CAFA, and at 24 hours after device removal for the 20 patients who received treatment for at least 48 hours. The findings are consistent with an improvement (upward shift) in the Starling curve, which persisted 24 hours after discontinuation of treatment.

Weak inverse correlations were observed between the 24-hour change from baseline in both SVR (r=0.42; P=0.048) and PCWP (r=0.40; P=0.056) with baseline CI. Patients with lower baseline CI tended to show greater reductions in SVR and PCWP with treatment.

Serum creatinine trended downward from baseline over the first 48 hours of treatment, with the effect sustained at 72 hours (overall P=0.095; Figure 5). In the US patients only, serum creatinine levels were repeated an average of 3 days after discontinuation of treatment, and at that time, levels had increased again from 1.21±0.35 mg% on treatment day 3 to 1.43±0.39 mg%.
TABLE 1. Baseline Characteristics

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age, y</th>
<th>Gender</th>
<th>Diagnosis</th>
<th>EF, %</th>
<th>Medicines</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>64</td>
<td>M</td>
<td>Ischemic cardiomyopathy</td>
<td>25</td>
<td>Dobutamine</td>
</tr>
<tr>
<td>2</td>
<td>53</td>
<td>M</td>
<td>Graft arteriosclerosis</td>
<td>20</td>
<td>Dopamine</td>
</tr>
<tr>
<td>3</td>
<td>70</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>8</td>
<td>Dopamine</td>
</tr>
<tr>
<td>4</td>
<td>40</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>15</td>
<td>Dobutamine, milrinone</td>
</tr>
<tr>
<td>5</td>
<td>51</td>
<td>M</td>
<td>Ischemic cardiomyopathy</td>
<td>15</td>
<td>Dobutamine, milrinone</td>
</tr>
<tr>
<td>6</td>
<td>67</td>
<td>M</td>
<td>Ischemic cardiomyopathy</td>
<td>NA</td>
<td>Dobutamine, dopamine</td>
</tr>
<tr>
<td>7</td>
<td>65</td>
<td>F</td>
<td>Valvular heart disease</td>
<td>20</td>
<td>Dobutamine, dopamine</td>
</tr>
<tr>
<td>8</td>
<td>60</td>
<td>M</td>
<td>Ischemic cardiomyopathy</td>
<td>28</td>
<td>Dobutamine, milrinone</td>
</tr>
<tr>
<td>9</td>
<td>52</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>19</td>
<td>Dobutamine</td>
</tr>
<tr>
<td>10</td>
<td>51</td>
<td>M</td>
<td>Ischemic cardiomyopathy</td>
<td>20</td>
<td>Dobutamine, nitroprusside</td>
</tr>
<tr>
<td>11</td>
<td>69</td>
<td>M</td>
<td>Ischemic cardiomyopathy</td>
<td>15</td>
<td>Dobutamine</td>
</tr>
<tr>
<td>12</td>
<td>52</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>22</td>
<td>Dobutamine</td>
</tr>
<tr>
<td>13</td>
<td>51</td>
<td>F</td>
<td>Dilated cardiomyopathy</td>
<td>17</td>
<td>Milrinone</td>
</tr>
<tr>
<td>14</td>
<td>60</td>
<td>M</td>
<td>Ischemic cardiomyopathy</td>
<td>25</td>
<td>Milrinone</td>
</tr>
<tr>
<td>15</td>
<td>54</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>22</td>
<td>Milrinone</td>
</tr>
<tr>
<td>16</td>
<td>35</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>8</td>
<td>Dobutamine, milrinone</td>
</tr>
<tr>
<td>17</td>
<td>46</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>10</td>
<td>Dobutamine</td>
</tr>
<tr>
<td>18</td>
<td>49</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>15</td>
<td>Dobutamine, milrinone, nesiritide</td>
</tr>
<tr>
<td>19</td>
<td>53</td>
<td>M</td>
<td>Ischemic cardiomyopathy</td>
<td>19</td>
<td>Dobutamine, dopamine, milrinone, nesiritide</td>
</tr>
<tr>
<td>20</td>
<td>26</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>12</td>
<td>Dobutamine, milrinone</td>
</tr>
<tr>
<td>21</td>
<td>75</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>18</td>
<td>Milrinone</td>
</tr>
<tr>
<td>22</td>
<td>44</td>
<td>F</td>
<td>Dilated cardiomyopathy</td>
<td>24</td>
<td>Dobutamine, milrinone</td>
</tr>
<tr>
<td>23</td>
<td>70</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>13</td>
<td>Dobutamine, milrinone</td>
</tr>
<tr>
<td>24</td>
<td>49</td>
<td>M</td>
<td>Dilated cardiomyopathy</td>
<td>12</td>
<td>Milrinone</td>
</tr>
</tbody>
</table>

Adverse Effects

A total of 8 patients experienced complications during treatment. One death (described above) was not considered related to the device. The remaining 7 patients had no lasting sequelae. In 2 patients, the percutaneous device was removed on the second day because of bleeding from the insertion site. In both cases, bleeding was controlled by manual compression after device removal. In 1 patient, during surgical inflow cannula insertion, there was dissection of the profunda femoris artery, which was surgically repaired without sequelae. In 1 patient, the right iliac artery was dissected during sheath exchange after removal of the pigtail cannula. This event was managed conservatively, without sequelae. In 1 patient, the percutaneous device was removed on the fourth day because of loss of left pedal pulse, which returned immediately after device removal. In 2 patients, the device was removed owing to thrombosis within the cannulas, which resulted in reduced flow. In both patients, 1 of whom had deficiency of antithrombin III, anticoagulation was subtherapeutic. Neither patient experienced any clinical embolic events.

NA indicates not available.

TABLE 2. Hemodynamics Over the Initial 24 Hours of Treatment (n=23; Mean±SD)

|                          | Baseline | 1     | 2     | 4     | 8     | 12    | 16    | 20    | 24    | Overall
|--------------------------|----------|-------|-------|-------|-------|-------|-------|-------|-------|----------
| PAP, mm Hg               | 40.9±6.1 | 37.3±8.8* | 38.5±9.9 | 38.4±9.5 | 37.8±10.7 | 34.9±8.4* | 34.5±8.9* | 34.8±8.7* | 34.6±9.8* | P=0.0005 |
| SVR, dyne·s·cm⁻⁵         | 1545±486 | 1352±500 | 1289±508* | 1233±500* | 1230±456* | 1179±429* | 1323±498* | 1203±478* | 1195±421* | NS       |
| PCWP, mm Hg              | 26±4.9   | 24.8±7.2* | 24.3±8.6* | 24.5±8.3* | 24.3±8.9 | 21.8±8.1* | 21.7±7.2* | 21.1±6.6* | 21.8±8.6* | P=0.0014 |
| HR, bpm                  | 88±18    | 90±17  | 90±16  | 88±17  | 92±16  | 92±16  | 89±18  | 89±18  | 88±18  | NS       |
| BP, mm Hg                | 76.9±9.3 | 72.4±10.5* | 72.7±9.9 | 70.3±9.2* | 69.9±9.4* | 67.3±8.1* | 70.1±8.9* | 68.5±10.8* | 68.7±12.5* | P=0.01   |

BP indicates mean arterial pressure; HR, heart rate; PAP, mean pulmonary artery pressure; and SVR, pulmonary vascular resistance. *P<0.05 vs baseline.

†By repeated-measures linear trend analysis.
**TABLE 3. Hemodynamics Over 72 Hours of Treatment and After Device Removal for Those Patients With at Least 48 Hours of Device Treatment (n=20; Mean±SD)**

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>8</th>
<th>16</th>
<th>24</th>
<th>32</th>
<th>40</th>
<th>48</th>
<th>56</th>
<th>64</th>
<th>72</th>
<th>x+12</th>
<th>x+24</th>
<th>Overall Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PMP, mm Hg</strong></td>
<td>28.5±4.9</td>
<td>25.8±8.3</td>
<td>22.8±6.7*</td>
<td>22.3±9.0*</td>
<td>23.6±6.1*</td>
<td>25.0±7.0*</td>
<td>23.8±7.6*</td>
<td>22.6±7.7*</td>
<td>21.8±6.5*</td>
<td>19.8±7.0*</td>
<td>19.7±6.8*</td>
<td>21.2±6.6*</td>
<td>P&lt;0.0001</td>
</tr>
<tr>
<td><strong>PAP, mm Hg</strong></td>
<td>41.3±6.1</td>
<td>39.9±9.8</td>
<td>36.1±8.4*</td>
<td>35.7±9.5*</td>
<td>34.9±7.9*</td>
<td>37.4±8.4*</td>
<td>37.3±9.7*</td>
<td>37.9±9.2*</td>
<td>35.9±10.4*</td>
<td>35.2±9.3*</td>
<td>33.2±6.1*</td>
<td>36.2±8.0*</td>
<td>P&lt;0.0001</td>
</tr>
<tr>
<td><strong>CI, L·min⁻¹·m⁻²</strong></td>
<td>1.97±0.44</td>
<td>2.10±0.55</td>
<td>2.03±0.35</td>
<td>2.09±0.45</td>
<td>2.08±0.37</td>
<td>2.23±0.50*</td>
<td>2.19±0.51</td>
<td>2.22±0.52</td>
<td>2.24±0.50*</td>
<td>2.27±0.43*</td>
<td>2.37±0.50*</td>
<td>2.34±0.54*</td>
<td>P=0.0013</td>
</tr>
<tr>
<td><strong>HR, bpm</strong></td>
<td>89±18</td>
<td>93±17</td>
<td>89±18</td>
<td>90±19</td>
<td>90±16</td>
<td>89±17</td>
<td>90±18</td>
<td>90±17</td>
<td>90±15</td>
<td>90±15</td>
<td>93±16</td>
<td>90±17</td>
<td>NS</td>
</tr>
<tr>
<td><strong>BP, mm Hg</strong></td>
<td>74.7±6.6</td>
<td>70.7±8.9</td>
<td>69.8±8.2*</td>
<td>67.9±11.6</td>
<td>69.2±6.6*</td>
<td>70.4±11.2</td>
<td>68.1±8.3*</td>
<td>66.0±9.0*</td>
<td>68.2±9.7*</td>
<td>69.2±10.9*</td>
<td>67.5±5.4*</td>
<td>68.4±8.5*</td>
<td>P&lt;0.0001</td>
</tr>
<tr>
<td><strong>SVR, dyn·s·cm⁻³</strong></td>
<td>1413±453</td>
<td>1224±419</td>
<td>1208±363</td>
<td>1177±362</td>
<td>1208±350</td>
<td>1186±412</td>
<td>1170±396*</td>
<td>1086±350</td>
<td>1142±386*</td>
<td>1136±381*</td>
<td>1051±326*</td>
<td>1037±292*</td>
<td>P&lt;0.0008</td>
</tr>
<tr>
<td><strong>PVR, dyn·s·cm⁻³</strong></td>
<td>274±114</td>
<td>288±142</td>
<td>284±92</td>
<td>262±138</td>
<td>231±104</td>
<td>235±73</td>
<td>235±106</td>
<td>250±92</td>
<td>258±109</td>
<td>272±107</td>
<td>242±66</td>
<td>256±78</td>
<td>NS</td>
</tr>
</tbody>
</table>

BP indicates mean arterial pressure; HR, heart rate; PAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; x+12, 12 hours after device removal; and x+24, 24 hours after device removal.

*P<0.05 vs baseline.
†By repeated-measures linear trend analysis, including all values from baseline through 72 hours.

**Discussion**

Despite substantial advances in medical treatment for heart failure, hospitalizations for this condition continue to be common, representing a major source of morbidity and cost.1 Heart failure exacerbations are characterized by manifestations of volume overload, low cardiac output, or both.10,11 Medical treatment, including intravenous diuretics, vasodilators, and inotropic agents, are not uniformly successful in achieving the desired clinical improvement and are suspected of contributing to adverse clinical outcomes.12–18 In the present study of patients with severe heart failure exacerbation and persistent hemodynamic derangement despite intravenous diuretic and inotropic and/or vasodilator therapy, we observed that CAFA, with the Cancion system, markedly improved PCWP, pulmonary artery pressure, and CI in association with reduced SVR. Hemodynamic improvement was still present after discontinuation of flow augmentation. Serum creatinine trended downward during treatment. This initial human investigation provides encouraging evidence for a potentially important clinical role for this novel treatment.

Ongoing investigation is directed toward determining a role for CAFA in facilitating recovery from heart failure exacerbation refractory to conventional medical treatment.

CAFA differs from all previously applied forms of circulatory assistance. With an arterial-to-arterial flow circuit, drawing blood from the iliac artery and returning it to the descending thoracic aorta, the Cancion system does not assume or directly augment cardiac output. Previous devices, including one that is percutaneously implanted with 15F to 21F cannulas (CardiacAssist, Inc),19 are designed to directly augment cardiac output, in parallel with the intrinsic circulation. These auxiliary flow systems require high-flow pumps, large-bore cannulas, and surgical or highly invasive implantation techniques. They are, therefore, reserved for the most severely ill patients who are, however, candidates for complex, invasive procedures. Although the initial 5 patients enrolled in the present study had surgically implanted cannulas, in the subsequent 19 patients, CAFA was achieved with a simple percutaneous procedure, performed in the catheterization laboratory. CAFA was provided by a centrifugal pump that generates up to 1.5 L/min of flow.

**Figure 2.** Effects of CAFA on PCWP (mean±SEM) during the first 24 hours of treatment in US patients (n=12), in whom serial measurements were made during the 24 hours preceding device implantation. Measurements remained stable before initiation of device treatment, after which PCWP decreased rapidly and continued to decrease over the subsequent 12 hours.
One potential explanation for hemodynamic improvement with CAFA relates to cardiac unloading through conservation of forward flow throughout the cardiac cycle. Additionally, the early and progressive decrease in SVR suggests that augmentation of flow within the aorta in patients with reduced cardiac output stimulates vasodilation within downstream resistance arterial beds through flow-mediated vasodilation. Utilizing an in vitro model of the central arterial circulation, Gharib and Beizaie observed that during low-flow states, the flow pattern is perturbed, with reversal of blood flow along the aortic borders during diastole. CAFA favorably alters this pattern by providing antegrade flow throughout the cardiac cycle. Such changes in arterial flow patterns are likely to have a major influence on endothelial release of vasoactive mediators, such as nitric oxide, as has been demonstrated by Lu and Kassab.

Our finding in the present study that the magnitude of the observed decrease in SVR and in PCWP correlated inversely with baseline CI (that is, patients with the lowest baseline CI showed the greatest magnitude of response to CAFA) is consistent with the hypothesis that a low-flow state within the aorta signals downstream vasoconstriction, and augmentation of aortic flow reverses this effect.

In a study by Haithcock et al., 4 hours of CAFA within a microembolic, ischemic, chronic myopathic canine model achieved progressive reduction in left heart filling pressure associated with reductions in LV volumes and increases in stroke volume, cardiac output, and EF. There was no discernible change in heart rate or arterial pressure. Wasler et al. previously reported the first human application of this technique in a patient with ischemic cardiomyopathy who was admitted for exacerbation of heart failure. During 3 days of treatment with CAFA, there were substantial decreases in PCWP, LV dimensions, and serum creatinine, with increases in CI and EF.

We enrolled patients with severe exacerbations of chronic heart failure, characterized by high cardiac filling pressures...
and low CI, whose conditions were poorly responsive to intravenous diuretics and inotropes and/or vasodilators. Our observations of marked improvement in hemodynamics, which persisted 24 hours after discontinuation of CAFA, support a role for this form of treatment as an adjunct to medical therapy in patients requiring hospitalization because of worsening heart failure. An increase in CI (excluding augmented aortic flow), at a time when PCWP is markedly reduced from baseline, indicates that the LV has moved to a more favorable Starling curve. CAFA treatment is likely to break a vicious circle characterized by reduced aortic flow, worsening peripheral vasoconstriction, increasing filling pressure, and further reduction in cardiac output, providing an opportunity for sustained clinical benefit. Furthermore, a prolonged reduction in filling pressures and SVR, with a reduction in LV volumes (and presumed reduction in wall stress) as observed in animal investigations, may achieve recovery in myocardial function.

The downward trend in serum creatinine also favors clinical usefulness for this technique. There has been substantial recent attention given to the “cardio-renal syndrome” of severe heart failure, with growing evidence that worsening renal function during hospitalization carries a poor prognosis. It is possible that CAFA directly augments renal blood flow, or alternatively, that the same signals responsible for downstream vasodilation (eg, nitric oxide) favorably affect glomerular and/or tubular function. Ongoing animal investigations are directed toward further exploration of the mechanisms of CAFA action on central hemodynamics, as well as on renal hemodynamics and glomerular and tubular function.

Observations in the present study justify investigations of the potential for translating the hemodynamic and renal benefits of CAFA treatment into improved symptoms and clinical outcomes. The ongoing Multi-center Trial of the Orqis Medical Cancion System for the Enhanced Treatment...
of Heart Failure Unresponsive to Medical Therapy (MOMENTUM) is a randomized, controlled trial of the effects of CAFA therapy added to medical therapy versus medical therapy alone on both hemodynamics and clinical outcomes.

In summary, CAFA therapy with the Orqis Cancion system achieved significant improvement in hemodynamics that were still present after termination of treatment in patients hospitalized with an exacerbation of chronic heart failure that had been inadequately responsive to medical therapy, including intravenous diuretics and inotropes and/or vasodilators. These benefits were most pronounced in patients with lower baseline cardiac indices and were accompanied by beneficial trends in serum creatinine. Although the precise mechanism for CAFA benefit continues to be explored, it is possible that effects derive, at least in part, from modulation of signals emanating from the aorta responsible for downstream vascular effects. An ongoing investigation is exploring a potential role of nitric oxide in mediating such effects. CAFA, achieved through a readily implanted percutaneous device, represents a promising mode of therapy for patients with severe heart failure. The clinical impact of this mode of therapy is currently under investigation.

Acknowledgment

This work was funded by Orqis Medical Corporation, Lake Forest, Calif.

Disclosure

Drs Czerska, Bohn, Oren, Sadowski, Khanal, Abraham, Wasler, Dahm, Gavazi, Gradinac, Legrand, Mohacs, Poesl, Radovancevic, Van Bakel, Zile, Cabuay, and Bartus are Principal Investigators for Orqis Medical Corporation. Dr Jansen was an employee of Orqis Medical. Dr Konstam is a part-time employee of Orqis Medical, serving as Medical Director.

References

Continuous Aortic Flow Augmentation: A Pilot Study of Hemodynamic and Renal Responses to a Novel Percutaneous Intervention in Decompensated Heart Failure


*Circulation.* 2005;112:3107-3114; originally published online November 7, 2005; doi: 10.1161/CIRCULATIONAHA.105.555367

*Circulation* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/112/20/3107

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Circulation* is online at:
http://circ.ahajournals.org//subscriptions/